Decheng Capital LLC Q1 2025 Filing
Filed May 8, 2025
Portfolio Value
$356.5B
Holdings
27
Report Date
Q1 2025
Filing Type
13F-HR
All Holdings (27 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | CGONCG ONCOLOGY INC | 6,371,669 | $156.0B | 43.77% | |
| 2 | NUVBNuvation Bio Inc. | 25,954,439 | $45.7B | 12.81% | |
| 3 | AARDAARDVARK THERAPEUTICS INC | 3,917,299 | $29.4B | 8.25% | |
| 4 | UPBUpstream Bio Inc. | 3,285,293 | $20.1B | 5.64% | |
| 5 | NAMSNEWAMSTERDAM PHARMA CO NV | 770,000 | $15.8B | 4.42% | |
| 6 | KRYSKRYSTAL BIOTECH INC | 65,000 | $11.7B | 3.29% | |
| 7 | RVMDREVOLUTION MEDICINES INC(NSM) | 226,000 | $8.0B | 2.24% | |
| 8 | MRUSMERUS NV | 189,098 | $8.0B | 2.23% | |
| 9 | BYSIBeyondSpring Inc. | 4,882,651 | $7.0B | 1.96% | |
| 10 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 171,600 | $6.7B | 1.88% | |
| 11 | LYELLyell Immunopharma, Inc. | 11,909,341 | $6.4B | 1.80% | |
| 12 | RCUSArcus Biosciences, Inc | 808,789 | $6.3B | 1.78% | |
| 13 | ACRSAclaris Therapeutics, Inc. | 4,041,736 | $6.2B | 1.73% | |
| 14 | CRNXCRINETICS PHARMACEUTICALS IN | 177,958 | $6.0B | 1.67% | |
| 15 | CYTKCYTOKINETICS INC | 100,000 | $4.0B | 1.13% | |
| 16 | LEGNLEGEND BIOTECH CORP-ADR | 100,000 | $3.4B | 0.95% | |
| 17 | ACLXARCELLX INC | 50,000 | $3.3B | 0.92% | |
| 18 | ZNTLZentalis Pharmaceuticals Inc. | 2,019,762 | $3.2B | 0.90% | |
| 19 | AURAAura Biosciences, Inc. | 515,555 | $3.0B | 0.85% | |
| 20 | BNTXBiontech SE-ADR | 20,000 | $1.8B | 0.51% | |
| 21 | EQEquillium Inc. | 4,447,308 | $1.7B | 0.49% | |
| 22 | FDMT4D MOLECULAR THERAPEUTICS IN | 335,515 | $1.1B | 0.30% | |
| 23 | ILMNIllumnia, Inc. | 11,749 | $932.2M | 0.26% | |
| 24 | PYXSPyxis Oncology, Inc (formerly Apexigen) | 326,810 | $320.2M | 0.09% | |
| 25 | GRALGRAIL INC | 9,684 | $247.3M | 0.07% | |
| 26 | VERAVERA THERAPEUTICS INC | 4,495 | $108.0M | 0.03% | |
| 27 | NUVB/WSNuvation Bio Inc. | 646,057 | $44.0M | 0.01% |